This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fass, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fass, R. J.

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1979 October; 16(4): 503-509
Copyright © 1979, American Society for Microbiology. All Rights Reserved.

In Vitro Activity of LY127935

Robert J. Fass

1 Division of Infectious Diseases, Department of Medicine, The Ohio State University College of Medicine, Columbus, Ohio 43210

ABSTRACT

LY127935 is a unique new ß-lactam antibiotic. Its activity against 536 clinical isolates was studied by using microdilution methods of susceptibility testing and compared with the activities of cefamandole, cefoxitin, and cephalothin. The lowest concentrations required to inhibit at least 90% of strains tested (MIC90S) of LY127935 for Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae ranged from 2 to 8 µg/ml. The MIC90S for other staphylococci and streptococci were higher. The MIC90S for Enterobacteriaceae and Pseudomonas species ranged from 0.12 to 8 µg/ml and 8 to >32 µg/ml, respectively. The MIC90S for anaerobes ranged from 2 to >32 µg/ml. As determined by MIC90S, LY127935 was consistently the least active antibiotic against facultatively anaerobic gram-positive cocci and the most active against aerobic and facultatively anaerobic gram-negative bacilli. Its position with respect to activity against anaerobes varied from being the most active against Bacteroides fragilis and Clostridium perfringens to the least active against anaerobic cocci. In a population of multidrug-resistant isolates, concentrations of 8 µg or less of LY127935 per ml inhibited 82% of Enterobacteriaceae; concentrations of 32 µg or less per ml inhibited 100% of Enterobacteriaceae and 40% of P. aeruginosa. Increasing the inoculum size by 100-fold did not increase the minimal inhibitory concentrations of LY127935 or cefoxitin but did increase minimal inhibitory concentrations of cefamandole and cephalothin for some Enterobacteriaceae. All four drugs were bactericidal; minimal bactericidal concentrations were the same or one concentration higher than minimal inhibitory concentrations for 91 to 96% of strains tested. The broad spectrum and marked in vitro activity of LY127935 make it a promising new antibiotic.

Antimicrob Agents Chemother. 1979 October; 16(4): 503-509
Copyright © 1979, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Stellato, T. A., Danziger, L. H., Hau, T., Gauderer, M. W L., Ferron, J. L., Gordon, N. (1988). Moxalactam vs Tobramycin-Clindamycin: A Randomized Trial in Secondary Peritonitis. Arch Surg 123: 714-717 [Abstract]  
  • Axelrod, J. L., Kochman, R. S. (1982). Moxalactam Concentration in Human Aqueous Humor After Intravenous Administration. Arch Ophthalmol 100: 1334-1336 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»